

## ***Good Laboratory Practice Guide Table of Contents***

Chapter 1. EXECUTIVE SUMMARY .....	6
Chapter 2. INTRODUCTION.....	9
Quality Assurance.....	9
Good Laboratory Practice and the Transfer of Technology.....	11
The Cost of GLP Non-compliance .....	14
Chapter 3. INTERNATIONAL REGULATIONS GOVERNING GLP .....	15
Chronology and Current Regulations.....	15
United States.....	15
The Organization for Economic Cooperation and Development (OECD) .....	17
Europe .....	18
Canada.....	19
Japan.....	20
Comparison of the Regulations.....	22
Chapter 4. CRITICAL COMPLIANCE ISSUES .....	32
Organization and Personnel (Subpart B, §58.29–35) .....	32
Matrix Organization.....	32
Personnel Qualifications, Training, and Behavior (§58.29 and 58.31).....	34
Management Responsibilities (§58.31).....	38
Analytical Method Qualification and Validation.....	42
Specific Appointments: The Study Director (§58.33) .....	46
The Quality Assurance Unit (§58.35).....	49
Facilities (Subpart C, §58.41 – 51).....	55
Containment Issues .....	56
Animal Unit Design .....	57
Equipment (Subpart D, §58.61–63).....	59
Testing Facilities Operation (Subpart E §58.81 –90) .....	63
Standard Operating Procedures (§58.81) .....	63
Guide to SOP Writing .....	65
Reagents and Solutions (§58.83).....	69

Animal Care (§58.90).....	70
Test and Control Articles (Subpart F, §58.105–113).....	73
Protocol for and Conduct of a Study (Subpart G, §58.120–130) .....	76
The Study Protocol (§58.120).....	76
Conduct of the Study (§58.130).....	78
Recording of Data .....	79
Electronic Data Management .....	80
Records and Reports (Subpart J, §58.185–195) .....	82
The Final Report of the Study (§58.185) .....	82
Archiving the Data (§58.190).....	85
Retention of Archived Records and Specimens (§58.195) .....	86
Form of Retained Records (§58.195g).....	86
Transfer of Records (§58.195h).....	87
<b>Chapter 5. SUBMITTING NON-CLINICAL STUDY FINDINGS IN CLINICAL TRIAL</b>	
<b>APPLICATIONS .....</b>	<b>88</b>
IND Contents According to FDA .....	88
The ICH Common Technical Document.....	90
Non-clinical Summaries and Tables .....	92
Order of Presentation of Information within Sections .....	93
Module 4—Non-clinical Data .....	98
<b>Chapter 6. GLP INSPECTIONS AND STUDY AUDITS.....</b>	<b>101</b>
What Are Inspections and Audits? .....	101
Establishment Inspections .....	102
Key Inspection Points .....	104
Study Audits.....	106
Establishment Inspection Report (EIR).....	108
Deviations which are not required to be notified by FDA 483 are:.....	109
How to Survive Inspections and Audits.....	110
Before—Preparing for the Inspection .....	110
During—Inspection Days.....	114
After—Dealing with the Report .....	117

How Others Fared—Excerpts from Form 483 .....	118
Appendix 1. INSPECTION (AUDIT) FORMS.....	123
Appendix 2. FURTHER READING.....	147
Advisory Bodies, Publications and Web Sites .....	147
References .....	150